The Drug Regulatory Authority of Pakistan (DRAP) has put a new DRAP online licensing system into use, letting pharmaceutical firms and other sellers file applications for licences and product registration electronically. According to a memorandum from the authority, the system has been set up on DRAP's website and covers its Health and Over-the-Counter (HOTC) Division. The step follows the notification of the Alternative Medicines and Health Products Rules, 2026, issued by the government in November.
How the new system works
The rules were notified through S.R.O. 2117(I)/2026 on November 16, 2026. An S.R.O., or statutory regulatory order, is the formal notice the government uses to bring in rules of this kind. Stakeholders can now use the DRAP online licensing system to send licence and product registration requests through the DRAP website.
The memorandum presents the change as part of DRAP's wider digital transformation, with aims that include more openness, better efficiency and easier access to regulatory services.
Fees and applicants who already paid
DRAP has also updated its online fee portal so that it matches the fee changes set by the new rules. Applicants will need to generate a fresh fee challan, the payment slip used for each fee, before filing. People who paid before the change will need to pay any shortfall through the portal, where it applies.
The authority has urged medicine makers, chemists and druggists, and manufacturers of nutraceuticals (health and dietary supplements) to follow the new rules, online steps and fee changes closely, so that their cases keep moving.
Aasan alfaaz mein
DRAP ne dawai banane walon aur bechne walon ke liye licence aur product registration ka online nizam shuru kar diya hai. Ab darkhast DRAP ki website par jama ho sakti hai. Fees ka naya nizam online fee portal par lagu hai, aur jin logon ne pehle fees di thi unhe farq ki raqam bhi jama karni ho sakti hai. Chemists aur druggists ke liye iska matlab hai ke naye qawaid aur online tareeqay ko samajh kar chalna zaroori hai.











